Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Recruiting now · Not applicable

Conditions studied: Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma

In brief

This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.

Key facts

Study ID

NCT06446661

Run by

University of Chicago

People needed

48

Starts

2026-05-19

Expected to finish

2028-06-15

Last updated by the study team

2026-07-10

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of 15 years or older at time of enrollment
• Diagnosed with ALL or T-cell lymphoblastic lymphoma
• Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention.

You may not qualify if…

• Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
• Patient does not wish to participate
• Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.

Where it is running

• University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.